List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8406607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. New England Journal of Medicine, 2008, 359, 2233-2244.	13.9	1,273
2	Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Medicine, 1995, 1, 129-134.	15.2	919
3	Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries. Aids, 2012, 26, 2039-2052.	1.0	382
4	Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 65-71.	0.9	361
5	Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. New England Journal of Medicine, 2020, 383, 426-439.	13.9	265
6	High Incidence of Tuberculosis among HIVâ€Infected Infants: Evidence from a South African Populationâ€Based Study Highlights the Need for Improved Tuberculosis Control Strategies. Clinical Infectious Diseases, 2009, 48, 108-114.	2.9	240
7	Bacille Calmette-Guerin VaccineInduced Disease in HIV-Infected and HIV-Uninfected Children. Clinical Infectious Diseases, 2006, 42, 548-558.	2.9	228
8	Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet, The, 2013, 382, 1555-1563.	6.3	213
9	Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. New England Journal of Medicine, 2010, 363, 1510-1520.	13.9	210
10	Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ: British Medical Journal, 2007, 334, 136.	2.4	199
11	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. New England Journal of Medicine, 2012, 366, 2380-2389.	13.9	172
12	Diagnostic and Management Challenges for Childhood Tuberculosis in the Era of HIV. Journal of Infectious Diseases, 2007, 196, S76-S85.	1.9	167
13	Early antiretroviral therapy improves neurodevelopmental outcomes in infants. Aids, 2012, 26, 1685-1690.	1.0	155
14	Clinical presentation and outcome of Tuberculosis in Human Immunodeficiency Virus infected children on anti-retroviral therapy. BMC Pediatrics, 2008, 8, 1.	0.7	147
15	Primary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children. New England Journal of Medicine, 2011, 365, 21-31.	13.9	143
16	The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Frontiers in Immunology, 2017, 8, 1147.	2.2	133
17	HIV-Exposed Uninfected Infants are at Increased Risk for Severe Infections in the First Year of Life. Journal of Tropical Pediatrics, 2012, 58, 505-508.	0.7	130
18	Pattern of Infectious Morbidity in HIV-Exposed Uninfected Infants and Children. Frontiers in Immunology, 2016, 7, 164.	2.2	120

#	Article	IF	CITATIONS
19	Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Vaccine Journal, 2017, 24, .	3.2	112
20	Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. Aids, 2009, 23, 101-106.	1.0	110
21	Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bulletin of the World Health Organization, 2009, 87, 505-511.	1.5	102
22	Danish Bacille Calmette-Guerin Vaccine-Induced Disease in Human Immunodeficiency Virus-Infected Children. Clinical Infectious Diseases, 2003, 37, 1226-1233.	2.9	101
23	Paediatric HIV/AIDS disclosure: towards a developmental and process-oriented approach. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 811-816.	0.6	99
24	Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological Issues for Conducting and Reporting Research Evaluations of Tuberculosis Diagnostics for Intrathoracic Tuberculosis in Children. Consensus From an Expert Panela. Journal of Infectious Diseases, 2012, 205, S209-S215.	1.9	99
25	Severe Infections in HIV-Exposed Uninfected Infants: Clinical Evidence of Immunodeficiency. Journal of Tropical Pediatrics, 2010, 56, 75-81.	0.7	96
26	The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infectious Diseases, The, 2008, 8, 67-80.	4.6	95
27	Challenges to Pediatric HIV Care and Treatment in South Africa. Journal of Infectious Diseases, 2007, 196, S474-S481.	1.9	94
28	Effect of HIV Infection Status and Antiâ€Retroviral Treatment on Quantitative and Qualitative Antibody Responses to Pneumococcal Conjugate Vaccine in Infants. Journal of Infectious Diseases, 2010, 202, 355-361.	1.9	92
29	Invasive disease due to extended spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal unit: the possible role of cockroaches. Journal of Hospital Infection, 2000, 44, 13-17.	1.4	90
30	The challenges of success: adolescents with perinatal HIV infection. Journal of the International AIDS Society, 2013, 16, 18650.	1.2	90
31	A Proposed Comprehensive Classification of Tuberculosis Disease Severity in Children. Pediatric Infectious Disease Journal, 2012, 31, 347-352.	1.1	85
32	High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureusin nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infectious Diseases, 2008, 8 40	1.3	82
33	The association between the ratio of monocytes:lymphocytes at age 3Âmonths and risk of tuberculosis (TB) in the first two years of life. BMC Medicine, 2014, 12, 120.	2.3	80
34	Antiretroviral Drugs for Preventing Mother-to-Child Transmission of HIV: A Review of Potential Effects on HIV-Exposed but Uninfected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 290-296.	0.9	76
35	Trends in paediatric bloodstream infections at a South African referral hospital. BMC Pediatrics, 2015, 15, 33.	0.7	75
36	Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome and Unmasking of Tuberculosis by Antiretroviral Therapy. Clinics in Chest Medicine, 2009, 30, 797-810.	0.8	74

#	Article	IF	CITATIONS
37	A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nature Communications, 2019, 10, 412.	5.8	73
38	Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. International Journal of Tuberculosis and Lung Disease, 2008, 12, 1376-9.	0.6	72
39	Antibody Responses to Vaccination among South African HIV-Exposed and Unexposed Uninfected Infants during the First 2 Years of Life. Vaccine Journal, 2013, 20, 33-38.	3.2	70
40	Altered Innate Immune Development in HIV-Exposed Uninfected Infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 245-255.	0.9	66
41	No evidence of HIV replication in children on antiretroviral therapy. Journal of Clinical Investigation, 2017, 127, 3827-3834.	3.9	66
42	Healthcare Providers' Perspectives on Discussing HIV Status with Infected Children. Journal of Tropical Pediatrics, 2006, 52, 293-295.	0.7	65
43	Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?. Journal of the International AIDS Society, 2014, 17, 18914.	1.2	65
44	Human metapneumovirus infection in hospital referred South African children. Journal of Medical Virology, 2004, 73, 486-493.	2.5	63
45	The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Review of Vaccines, 2014, 13, 619-630.	2.0	62
46	Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. Aids, 2018, 32, 189-204.	1.0	57
47	Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Preference and Adherence, 2016, 10, 683.	0.8	56
48	Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. Aids, 2014, 28, 531-541.	1.0	55
49	Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. International Journal of Tuberculosis and Lung Disease, 2008, 12, 225-7.	0.6	55
50	Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis. Antiviral Therapy, 2011, 16, 417-421.	0.6	53
51	Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. Journal of Infectious Diseases, 2015, 212, 39-43.	1.9	53
52	A Prospective Cohort Study of Common Childhood Infections in South African HIV-exposed Uninfected and HIV-unexposed Infants. Pediatric Infectious Disease Journal, 2017, 36, e38-e44.	1.1	52
53	Severe chickenpox after intranasal use of corticosteroids. Journal of Pediatrics, 1993, 123, 577-579.	0.9	51
54	Resistant Mycobacterium bovis Bacillus Calmette-Gu??rin Disease : Implications for Management of Bacillus Calmette-Gu??rin Disease in Human Immunodeficiency Virus-Infected Children. Pediatric Infectious Disease Journal, 2004, 23, 476-479.	1.1	51

#	Article	IF	CITATIONS
55	Management of upper respiratory tract infections in children. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2008, 50, 6-12.	0.2	50
56	Failure of Chemoprophylaxis With Standard Antituberculosis Agents in Child Contacts of Multidrug-Resistant Tuberculosis Cases. Pediatric Infectious Disease Journal, 2007, 26, 1142-1146.	1.1	49
57	Positive futures: a qualitative study on the needs of adolescents on antiretroviral therapy in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 751-758.	0.6	49
58	High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2016, 35, e1-e7.	1.1	49
59	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infectious Diseases, The, 2015, 15, 803-809.	4.6	47
60	Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosis–HIV Burden Setting. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 820-830.	2.5	46
61	The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax, 2011, 66, 496-501.	2.7	45
62	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. Pediatric Infectious Disease Journal, 2009, 28, 1125-1127.	1.1	44
63	TB and HIV in children – advances in prevention and management. Paediatric Respiratory Reviews, 2011, 12, 39-45.	1.2	44
64	Detecting Tuberculosis Infection in HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, e111-e118.	1.1	44
65	Plasma arginine vasopressin and the syndrome of innappropriate antidiuretic hormone secretion in tuberculous meningitis. Pediatric Infectious Disease Journal, 1991, 10, 837-842.	1.1	43
66	Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens. PLoS Medicine, 2008, 5, e176.	3.9	42
67	White Matter Signal Abnormalities in Children With Suspected HIV-related Neurologic Disease on Early Combination Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2014, 33, e207-e212.	1.1	42
68	Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. Pediatric Infectious Disease Journal, 1998, 17, 599-604.	1.1	42
69	Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clinical Infectious Diseases, 2016, 63, 1113-1121.	2.9	41
70	Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine. Aids, 2013, 27, 1583-1591.	1.0	40
71	Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. Journal of Pediatrics, 1994, 124, 967-971.	0.9	39
72	Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1194-1200.	0.6	39

#	Article	IF	CITATIONS
73	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. The Lancet Global Health, 2015, 3, e358-e359.	2.9	39
74	Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers. PLoS Medicine, 2012, 9, e1001273.	3.9	38
75	White Matter Abnormalities in Children with HIV Infection and Exposure. Frontiers in Neuroanatomy, 2017, 11, 88.	0.9	38
76	The First 5 Years of the Family Clinic for HIV at Tygerberg Hospital: Family Demographics, Survival of Children and Early Impact of Antiretroviral Therapy. Journal of Tropical Pediatrics, 2006, 52, 3-11.	0.7	36
77	Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure. Journal of Clinical Virology, 2015, 62, 48-53.	1.6	36
78	Early Antiretroviral Therapy in HIV-Infected Children Is Associated with Diffuse White Matter Structural Abnormality and Corpus Callosum Sparing. American Journal of Neuroradiology, 2016, 37, 2363-2369.	1.2	36
79	Placental pathology in HIV infection at term: a comparison with HIVâ€uninfected women. Tropical Medicine and International Health, 2017, 22, 604-613.	1.0	36
80	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials, 2020, 90, 105938.	0.8	36
81	Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy. The Lancet Child and Adolescent Health, 2020, 4, 688-698.	2.7	35
82	Ontogeny of Toll-Like Receptor Mediated Cytokine Responses of South African Infants throughout the First Year of Life. PLoS ONE, 2012, 7, e44763.	1.1	35
83	Burden, spectrum, and impact of healthcare-associated infection at a South African children's hospital. Journal of Hospital Infection, 2016, 94, 364-372.	1.4	34
84	Diagnostic dilemmas in abdominal tuberculosis in children. Pediatric Surgery International, 2001, 17, 111-115.	0.6	33
85	Nosocomial Pneumonia in Pediatric Patients. Paediatric Drugs, 2002, 4, 73-83.	1.3	33
86	Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018, 19, 237.	0.7	33
87	Raised intracranial pressure, the syndrome of inappropriate antidiuretic hormone secretion, and arginine vasopressin in tuberculous meningitis. Child's Nervous System, 1993, 9, 10-15.	0.6	32
88	Bacterial Disease and Antimicrobial Susceptibility Patterns in HIV-Infected, Hospitalized Children: A Retrospective Cohort Study. PLoS ONE, 2008, 3, e3260.	1.1	32
89	Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. , 2009, , CD006418.		32
90	Increased Microbial Translocation in â‰⊉80 Days Old Perinatally Human Immunodeficiency Virus-positive Infants as Compared With Human Immunodeficiency Virus-exposed Uninfected Infants of Similar Age. Pediatric Infectious Disease Journal, 2011, 30, 877-882.	1.1	32

#	Article	IF	CITATIONS
91	Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine, 2013, 31, 777-783.	1.7	32
92	Five year neurodevelopment outcomes of perinatally <scp>HIV</scp> â€infected children on early limited or deferred continuous antiretroviral therapy. Journal of the International AIDS Society, 2018, 21, e25106.	1.2	32
93	Apoptosis of CD4+ and CD8+ T Cells Isolated Immediately ex Vivo Correlates with Disease Severity in Human Immunodeficiency Virus Type 1 Infection. Pediatric Research, 1997, 42, 656-664.	1.1	32
94	Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infectious Diseases, The, 2022, 22, 1472-1483.	4.6	32
95	Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. Journal of Clinical Virology, 2006, 37, 68-71.	1.6	31
96	Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. Journal of Medical Virology, 2008, 80, 942-946.	2.5	31
97	Maternal postpartum depression and infant social withdrawal among human immunodeficiency virus (HIV) positive mother–infant dyads. Psychology, Health and Medicine, 2010, 15, 278-287.	1.3	31
98	Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants. Therapeutic Drug Monitoring, 2012, 34, 446-451.	1.0	31
99	Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. , 2012, , CD004772.		31
100	Pediatric meningitis in the western Cape Province of South Africa. Journal of Tropical Pediatrics, 1996, 42, 256-261.	0.7	30
101	Cohort Profile: The Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration. International Journal of Epidemiology, 2008, 37, 474-480.	0.9	30
102	Longitudinal increases of brain metabolite levels in 5-10 year old children. PLoS ONE, 2017, 12, e0180973.	1.1	30
103	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 433-438.	0.6	29
104	COVID-19 response in low- and middle-income countries: Don't overlook the role of mobile phone communication. International Journal of Infectious Diseases, 2020, 99, 334-337.	1.5	29
105	Maternal post-traumatic stress disorder, depression and alcohol dependence and child behaviour outcomes in mother–child dyads infected with HIV: a longitudinal study. BMJ Open, 2013, 3, e003638.	0.8	28
106	Surgical Masks Reduce Airborne Spread of <i>Pseudomonas aeruginosa</i> in Colonized Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 897-899.	2.5	28
107	Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. The Lancet Global Health, 2020, 8, e1249-e1250.	2.9	28
108	BCG and HIV reconsidered: Moving the research agenda forward. Vaccine, 2007, 25, 6565-6568.	1.7	27

#	Article	IF	CITATIONS
109	The challenge of chronic lung disease in HIVâ€ i nfected children and adolescents. Journal of the International AIDS Society, 2013, 16, 18633.	1.2	27
110	BCG vaccination in South African HIV-exposed infantsrisks and benefits. South African Medical Journal, 2009, 99, 88-91.	0.2	27
111	Pharmacokinetics of Isoniazid in Low-Birth-Weight and Premature Infants. Antimicrobial Agents and Chemotherapy, 2014, 58, 2229-2234.	1.4	26
112	Crossâ€cultural assessment of HIVâ€associated cognitive impairment using the Kaufman assessment battery for children: a systematic review. Journal of the International AIDS Society, 2017, 20, 21412.	1.2	26
113	HIV-associated CD4+/CD8+ depletion in infancy is associated with neurometabolic reductions in the basal ganglia at age 5 years despite early antiretroviral therapy. Aids, 2016, 30, 1353-1362.	1.0	25
114	Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial. Frontiers in Immunology, 2017, 8, 1162.	2.2	25
115	Antiviral Therapy of CMV Disease in Children. Advances in Experimental Medicine and Biology, 2011, 697, 243-260.	0.8	24
116	Sulfamethoxazole enhances the antimycobacterial activity of rifampicin. Journal of Antimicrobial Chemotherapy, 2012, 67, 2908-2911.	1.3	24
117	Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 161-169.	0.9	24
118	Infections in HIV-exposed Uninfected Children With Focus on Sub-Saharan Africa. Pediatric Infectious Disease Journal, 2014, 33, 1085-1086.	1.1	24
119	Altered brain morphometry in 7-year old HIV-infected children on early ART. Metabolic Brain Disease, 2018, 33, 523-535.	1.4	24
120	Bacteraemia in children in the south-western Cape. A hospital-based survey. South African Medical Journal, 1992, 81, 87-90.	0.2	24
121	Nosocomial infections in Black South African Children. Pediatric Infectious Disease Journal, 1989, 8, 676-682.	1.1	23
122	Paradoxical Tuberculosis associated Immune Reconstitution Inflammatory Syndrome Presenting with Chylous Ascites and Chylothorax in a HIV-1 Infected Child. Journal of Tropical Pediatrics, 2010, 56, 355-358.	0.7	23
123	HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 524-527.	0.6	23
124	Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge. Aids, 2018, 32, 629-634.	1.0	23
125	African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, e105-e114.	2.9	23
126	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1364-1366.	0.6	23

#	Article	IF	CITATIONS
127	Cerebrospinal fluid investigations in tuberculous meningitis. Annals of Tropical Paediatrics, 1991, 11, 241-246.	1.0	22
128	Poverty and Human Immunodeficiency Virus in Children. Annals of the New York Academy of Sciences, 2008, 1136, 21-27.	1.8	22
129	Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Medicine, 2009, 7, 67.	2.3	22
130	Attention Deficit Hyperactivity and Oppositional Defiance Disorder in HIV-Infected South African Children. Journal of Tropical Pediatrics, 2010, 56, 97-102.	0.7	22
131	Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine, 2015, 33, 4618-4622.	1.7	22
132	Isoniazid for preventing tuberculosis in HIV-infected children. The Cochrane Library, 2017, 2017, CD006418.	1.5	22
133	Strong sex bias in elite control of paediatric HIV infection. Aids, 2019, 33, 67-75.	1.0	22
134	Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life. Journal of Virology, 2020, 94, .	1.5	22
135	Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed. Aids, 2021, 35, 2327-2339.	1.0	22
136	Lipodystrophy syndrome in HIV-infected children on HAART. Southern African Journal of HIV Medicine, 2009, 10, 76.	0.3	22
137	Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet, The, 2002, 359, 992-993.	6.3	21
138	High tuberculosis exposure among neonates in a high tuberculosis and human immunodeficiency virus burden setting. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1040-1046.	0.6	21
139	High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatrics, 2012, 12, 183.	0.7	21
140	Children with Human Immunodeficiency Virus Infection Admitted to a Paediatric Intensive Care Unit in South Africa. Journal of Tropical Pediatrics, 2007, 53, 270-273.	0.7	20
141	Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine, 2011, 29, 6994-7001.	1.7	20
142	Tuberculosis and HIV—An Update on the "Cursed Duet―in Children. Frontiers in Pediatrics, 2019, 7, 159.	0.9	20
143	<scp>HIV</scp> â€l <scp>DNA</scp> decay is faster in children who initiate <scp>ART</scp> shortly after birth than later. Journal of the International AIDS Society, 2019, 22, e25368.	1.2	20
144	Face masks in the post-COVID-19 era: a silver lining for the damaged tuberculosis public health response?. Lancet Respiratory Medicine,the, 2021, 9, 340-342.	5.2	20

#	Article	IF	CITATIONS
145	Renal manifestations in children co-infected with HIV and disseminated tuberculosis. Pediatric Nephrology, 2010, 25, 1759-1763.	0.9	19
146	Bacteriologically confirmed tuberculosis in HIV-infected infants: disease spectrum and survival. International Journal of Tuberculosis and Lung Disease, 2011, 15, 770-775.	0.6	19
147	Interactive weekly mobile phone text messaging plus motivational interviewing in promotion of breastfeeding among women living with HIV in South Africa: study protocol for a randomized controlled trial. Trials, 2017, 18, 331.	0.7	19
148	Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV,the, 2019, 6, e32-e42.	2.1	19
149	The last and first frontier – emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. Journal of the International AIDS Society, 2015, 18, 20271.	1.2	19
150	Unexplained HIV-1 infection in children–documenting cases and assessing for possible risk factors. South African Medical Journal, 2004, 94, 188-93.	0.2	19
151	Acute aqueductal stenosis in a patient with Epstein-Barr virus infectious mononucleosis. Pediatric Infectious Disease Journal, 1994, 13, 224-227.	1.1	18
152	Poverty and tuberculosis: is it truly a simple inverse linear correlation?. European Respiratory Journal, 2009, 33, 943-944.	3.1	18
153	Spastic diplegia in children with <scp>HIV</scp> encephalopathy: first description of gait and physical status. Developmental Medicine and Child Neurology, 2014, 56, 686-694.	1.1	18
154	Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease, 2014, 18, 322-327.	0.6	18
155	Mass Needle Stick Injury in Children from the Western Cape. Journal of Tropical Pediatrics, 2006, 52, 192-196.	0.7	17
156	Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006–2017. Pediatric Infectious Disease Journal, 2020, 39, 127-133.	1.1	17
157	Making BCG vaccination programmes safer in the HIV era. Lancet, The, 2008, 372, 786-787.	6.3	16
158	Requirements for the clinical evaluation of new anti-tuberculosis agents in children. International Journal of Tuberculosis and Lung Disease, 2013, 17, 794-799.	0.6	16
159	Nevirapine Concentrations in Preterm and Low Birth Weight HIV-Exposed Infants. Pediatric Infectious Disease Journal, 2014, 33, 1231-1233.	1.1	16
160	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. Pediatric Infectious Disease Journal, 2014, 33, 846-854.	1.1	16
161	Severe manifestations of extrapulmonary tuberculosis in HIV-infected children initiating antiretroviral therapy before 2 years of age. Archives of Disease in Childhood, 2014, 99, 998-1003.	1.0	16
162	Larger Subcortical Gray Matter Structures and Smaller Corpora Callosa at Age 5 Years in HIV Infected Children on Early ART. Frontiers in Neuroanatomy, 2017, 11, 95.	0.9	16

#	Article	IF	CITATIONS
163	Perinatal HIV Infection or Exposure Is Associated With Low N-Acetylaspartate and Glutamate in Basal Ganglia at Age 9 but Not 7 Years. Frontiers in Human Neuroscience, 2018, 12, 145.	1.0	16
164	Prevalence of risk factors for chronic kidney disease in South African youth with perinatally acquired HIV. Pediatric Nephrology, 2019, 34, 313-318.	0.9	16
165	Insulin Resistance in South African Youth Living with Perinatally Acquired HIV Receiving Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2019, 35, 56-62.	0.5	16
166	Neurodevelopmental and behavioural outcomes of HIV-exposed uninfected and HIV-unexposed children at 2–3 years of age in Cape Town, South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 411-419.	0.6	16
167	It is time to consider thirdâ€line options in antiretroviralâ€experienced paediatric patients?. Journal of the International AIDS Society, 2011, 14, 55-55.	1.2	15
168	Tuberculosis in UK cities: workload and effectiveness of tuberculosis control programmes. BMC Public Health, 2011, 11, 896.	1.2	15
169	Premasticating Food for Weaning African Infants: A Possible Vehicle for Transmission of HIV. Pediatrics, 2011, 128, e579-e590.	1.0	15
170	Updated recommendations for the management of upper respiratory tract infections in South Africa. South African Medical Journal, 2015, 105, 345.	0.2	15
171	Longitudinal study on Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonization in HIV-infected and -uninfected infants vaccinated with pneumococcal conjugate vaccine. Vaccine, 2015, 33, 2662-2669.	1.7	15
172	Chest radiographic abnormalities in HIV-infected African children: a longitudinal study. Thorax, 2015, 70, 840-846.	2.7	15
173	A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries. PLoS ONE, 2019, 14, e0211155.	1.1	15
174	Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants. PLoS ONE, 2016, 11, e0148649.	1.1	14
175	Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. South African Medical Journal, 2011, 101, 655-8.	0.2	14
176	Low Rates of Hepatotoxicity in HIV-infected Children on Anti-retroviral Therapy with and without Isoniazid Prophylaxis. Journal of Tropical Pediatrics, 2010, 56, 159-165.	0.7	13
177	High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial [Short communication]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 192-195.	0.6	13
178	Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. International Journal of Tuberculosis and Lung Disease, 2013, 17, 26-31.	0.6	13
179	Corpus callosum thickness on mid-sagittal MRI as a marker of brain volume: a pilot study in children with HIV-related brain disease and controls. Pediatric Radiology, 2015, 45, 1016-1025.	1.1	13
180	The Effect of Deworming on Tests of Tuberculosis Infection in Children With Recent Tuberculosis Exposure. Pediatric Infectious Disease Journal, 2016, 35, 622-627.	1.1	13

#	Article	IF	CITATIONS
181	High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial. Pediatric Infectious Disease Journal, 2018, 37, e254-e256.	1.1	13
182	MRS suggests multi-regional inflammation and white matter axonal damage at 11Âyears following perinatal HIV infection. NeuroImage: Clinical, 2020, 28, 102505.	1.4	13
183	Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial. AIDS Research and Therapy, 2021, 18, 63.	0.7	13
184	Bioequivalence of Dispersed Stavudine: Opened versus Closed Capsule Dosing. Antiviral Therapy, 2011, 16, 1131-1134.	0.6	12
185	Clinical and immunological correlates of chest Xâ€ray abnormalities in HIVâ€infected South African children with limited access to antiâ€retroviral therapy. Pediatric Pulmonology, 2014, 49, 581-588.	1.0	12
186	Healthcare-associated infections in children: knowledge, attitudes and practice of paediatric healthcare providers at Tygerberg Hospital, Cape Town. Paediatrics and International Child Health, 2016, 36, 225-231.	0.3	12
187	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opinion on Pharmacotherapy, 2017, 18, 589-598.	0.9	12
188	Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV,the, 2021, 8, e149-e157.	2.1	12
189	Second Episode of Tuberculosis in an HIV-infected Child: Relapse or Reinfection?. Journal of Infection, 2000, 41, 100-103.	1.7	11
190	Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset. PLoS ONE, 2015, 10, e0145320.	1.1	11
191	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. International Journal of Antimicrobial Agents, 2015, 45, 413-419.	1.1	11
192	Impact of earlier combination antiretroviral therapy on outcomes in children. Current Opinion in HIV and AIDS, 2015, 10, 12-17.	1.5	11
193	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e1-e8.	0.9	11
194	A framework for preventing healthcare-associated infection in neonates and children in South Africa. South African Medical Journal, 2017, 107, 192.	0.2	11
195	Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines. Expert Review of Vaccines, 2019, 18, 95-104.	2.0	11
196	Horizontal HIV transmission to children of HIV-uninfected mothers: A case series and review of the global literature. International Journal of Infectious Diseases, 2020, 98, 315-320.	1.5	11
197	Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation. Journal of the International AIDS Society, 2021, 24, e25734.	1.2	11
198	BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial. JCI Insight, 2017, 2, e91963.	2.3	11

#	Article	IF	CITATIONS
199	Feeding practices and nutritional status of HIV-exposed and HIV-unexposed infants in the Western Cape. Southern African Journal of HIV Medicine, 2016, 17, 398.	0.3	11
200	Surveillance of healthcare-associated infection in hospitalised South African children: Which method performs best?. South African Medical Journal, 2016, 107, 56.	0.2	10
201	Functional Connectivity Alterations between Networks and Associations with Infant Immune Health within Networks in HIV Infected Children on Early Treatment: A Study at 7 Years. Frontiers in Human Neuroscience, 2017, 11, 635.	1.0	10
202	Multisystem impairment in South African adolescents with Perinatally acquired <scp>HIV</scp> on antiretroviral therapy (<scp>ART</scp>). Journal of the International AIDS Society, 2019, 22, e25386.	1.2	10
203	Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 2032-2034.	2.9	10
204	Impact of 1% chlorhexidine gluconate bathing and emollient application on bacterial pathogen colonization dynamics in hospitalized preterm neonates – A pilot clinical trial. EClinicalMedicine, 2021, 37, 100946.	3.2	10
205	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. The Lancet Child and Adolescent Health, 2021, 5, 642-651.	2.7	10
206	A Retrospective Study of Cryptosporidial Diarrhea in a Region with High HIV Prevalence. Journal of Tropical Pediatrics, 2011, 57, 289-292.	0.7	9
207	Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). South African Medical Journal, 2013, 103, 714.	0.2	9
208	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy, 2014, 58, 1084-1091.	1.4	9
209	Delayed BCG immunization does not alter antibody responses to EPI vaccines in HIV-exposed and -unexposed South African infants. Vaccine, 2016, 34, 3702-3709.	1.7	9
210	Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1060-1064.	0.6	9
211	Paediatric ART Adherence in South Africa: A Comprehensive Analysis. AIDS and Behavior, 2019, 23, 475-488.	1.4	9
212	Tuberculosis infection and disease in South African adolescents with perinatally acquired HIV on antiretroviral therapy: a cohort study. Journal of the International AIDS Society, 2021, 24, e25671.	1.2	9
213	HIV transmission between two siblings in Africa. Aids, 2000, 14, 896.	1.0	9
214	SURVEILLANCE OF TRANSMITTED RESISTANCE TO ANTIRETROVIRAL DRUG CLASSES AMONG YOUNG CHILDREN IN THE WESTERN CAPE PROVINCE OF SOUTH AFRICA. Pediatric Infectious Disease Journal, 2010, 29, 370-371.	1.1	9
215	Bacille Calmette-Guérin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed. International Journal of Tuberculosis and Lung Disease, 2020, 24, 732-734.	0.6	9
216	A child with neurobrucellosis. Annals of Tropical Paediatrics, 2003, 23, 145-148.	1.0	8

#	Article	IF	CITATIONS
217	Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C hildren with H IV E arly Antir etroviral Therapy (CHER) Study. BMC Research Notes, 2011, 4, 448.	0.6	8
218	HIV testing and antiretroviral therapy initiation at birth: Views from a primary care setting in Khayelitsha. Southern African Journal of HIV Medicine, 2015, 16, 376.	0.3	8
219	Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Children: A Systematic Review. Clinical Infectious Diseases, 2015, 60, S177-S181.	2.9	8
220	Assessment of terminal cleaning in pediatric isolation rooms: Options for low-resource settings. American Journal of Infection Control, 2016, 44, 1558-1564.	1.1	8
221	Diagnostic accuracy of the Molteno Adapted Scale for developmental delay in South African toddlers. Paediatrics and International Child Health, 2019, 39, 132-138.	0.3	8
222	Comparison of Lymphocyte Subset Populations in Children From South Africa, US and Europe. Frontiers in Pediatrics, 2020, 8, 406.	0.9	8
223	Recovery of HIV encephalopathy in perinatally infected children on antiretroviral therapy. Developmental Medicine and Child Neurology, 2020, 62, 1309-1316.	1.1	8
224	Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 324-331.	0.9	8
225	A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. Aids, 2010, 24, 2225-2232.	1.0	7
226	Oseltamivir Use in Low-Birth Weight Infants During the 2009 nH1N1 Influenza A Outbreak in the Western Cape, South Africa. Journal of Tropical Pediatrics, 2012, 58, 102-106.	0.7	7
227	Trough Lopinavir Concentrations in Preterm HIV-infected Infants. Pediatric Infectious Disease Journal, 2012, 31, 602-604.	1.1	7
228	Effects of postnatal interventions for the reduction of vertical HIV transmission on infant growth and nonâ€HIV infections: a systematic review. Journal of the International AIDS Society, 2013, 16, 18865.	1.2	7
229	Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children. Pediatric Infectious Disease Journal, 2014, 33, 50-56.	1.1	7
230	Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 138-144.	0.9	7
231	Complicated and Protracted Cryptococcal Disease in HIV-infected Children. Pediatric Infectious Disease Journal, 2015, 34, 62-65.	1.1	7
232	Second- and Third-line Antiretroviral Therapy for Children and Adolescents. Pediatric Infectious Disease Journal, 2017, 36, 492-499.	1.1	7
233	Use of Multiplex Quantitative PCR To Evaluate the Impact of Pneumococcal Conjugate Vaccine on Nasopharyngeal Pneumococcal Colonization in African Children. MSphere, 2017, 2, .	1.3	7
234	Early Breastfeeding Cessation Among HIV-Infected and HIV-Uninfected Women in Western Cape Province, South Africa. AIDS and Behavior, 2018, 22, 114-120.	1.4	7

#	Article	IF	CITATIONS
235	Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2–12 years on rifampicin for tuberculosis. Aids, 2019, 33, 2197-2203.	1.0	7
236	Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children. MBio, 2021, 12, .	1.8	7
237	Cavitation of the Ghon focus in an HIV-infected infant who acquired tuberculosis after the initiation of HAART. Southern African Journal of HIV Medicine, 2009, 10, 3.	0.3	7
238	Low-dose stavudine trials: a public health priority for developing countries. Southern African Journal of HIV Medicine, 2012, 13, 20-21.	0.3	7
239	HIV-Associated Tuberculosis in Children and Adolescents: Evolving Epidemiology, Screening, Prevention and Management Strategies. Pathogens, 2022, 11, 33.	1.2	7
240	Bacteremia in Human Immunodeficiency Virus-infected Children in Cape Town, South Africa. Pediatric Infectious Disease Journal, 2011, 30, 904-906.	1.1	6
241	Correlating brain volume and callosal thickness with clinical and laboratory indicators of disease severity in children with HIV-related brain disease. Child's Nervous System, 2014, 30, 1549-1557.	0.6	6
242	Antiretroviral Treatment Initiated in the First Month of Life. Pediatric Infectious Disease Journal, 2017, 36, 584-587.	1.1	6
243	Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. Journal of Clinical Virology, 2017, 95, 86-89.	1.6	6
244	Update on trends in childhood tuberculosis. Current Opinion in Pediatrics, 2018, 30, 152-160.	1.0	6
245	Management of adult patients with type 1 diabetes mellitus in Africa. Medicine (United States), 2020, 99, e20553.	0.4	6
246	Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age. Aids, 2021, 35, 1247-1252.	1.0	6
247	HIV-1 Persistence in Children during Suppressive ART. Viruses, 2021, 13, 1134.	1.5	6
248	Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. Southern African Journal of HIV Medicine, 2019, 20, 1008.	0.3	6
249	Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV,the, 2022, 9, e24-e31.	2.1	6
250	Cytomorphological patterns of <i>M. bovis</i> BCG and <i>M. tuberculosis</i> on fine needle aspiration biopsies: Does HIV make a difference?. Diagnostic Cytopathology, 2011, 39, 264-269.	0.5	5
251	The Cough Cylinder: a tool to study measures against airborne spread of (myco-) bacteria. International Journal of Tuberculosis and Lung Disease, 2013, 17, 46-53.	0.6	5
252	Pre-hospital management and risk factors in children with acute diarrhoea admitted to a short-stay ward in an urban South African hospital with a high HIV burden. SAJCH South African Journal of Child Health, 2013, 7, 84.	0.2	5

#	Article	IF	CITATIONS
253	Antiretroviral Regimens Containing a Single Protease Inhibitor Increase Risk of Virologic Failure in Young HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, 361-363.	1.1	5
254	Understanding NIH clinical case definitions for pediatric intrathoracic TB by applying them to a clinical trial. International Journal of Tuberculosis and Lung Disease, 2016, 20, 93-100.	0.6	5
255	â€~Of Mice and Dementia': A filmed conversation on the use of animals in dementia research. Dementia, 2018, 17, 1055-1063.	1.0	5
256	A treatmentâ€support intervention evaluated in South African paediatric populations with HIV infection or tuberculous meningitis. Tropical Medicine and International Health, 2018, 23, 1129-1140.	1.0	5
257	Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15–18 Months of Age Among Human Immunodeficiency Virus (HIV)–infected, HIV-exposed–uninfected, and HIV-unexposed Children. Clinical Infectious Diseases, 2019, 69, 687-696.	2.9	5
258	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
259	NeoCLEAN: a multimodal strategy to enhance environmental cleaning in a resource-limited neonatal unit. Antimicrobial Resistance and Infection Control, 2021, 10, 35.	1.5	5
260	Examining Associations of HIV and Iron Status with Nutritional and Inflammatory Status, Anemia, and Dietary Intake in South African Schoolchildren. Nutrients, 2021, 13, 962.	1.7	5
261	Why should we still care about the stavudine dose?. Southern African Journal of HIV Medicine, 2011, 12, 14.	0.3	5
262	A review of the use of blood and blood products in HIV-infected patients. Southern African Journal of HIV Medicine, 2012, 13, 87-104.	0.3	5
263	Apoptosis in HIV-1 Infection. Behring Institute Mitteilungen, 1996, , 220-31.	0.2	5
264	Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. Frontiers in Pediatrics, 0, 10, .	0.9	5
265	Endotracheal aspiration for the bacteriological diagnosis of nosocomial- and measles-associated pneumonia. Annals of Tropical Paediatrics, 1988, 8, 217-221.	1.0	4
266	Reply to — Apoptosis and HIV disease. Nature Medicine, 1995, 1, 387-387.	15.2	4
267	Viral isolates during febrile neutropaenia in children with cancer. Journal of Tropical Pediatrics, 2000, 46, 21-24.	0.7	4
268	Caring for our children. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2007, 49, 18-18.	0.2	4
269	Nitazoxanide for Severe Cryptosporidial Diarrhea in Human Immunodeficiency Virus Infected Children. Pediatric Infectious Disease Journal, 2008, 27, 1040-1041.	1.1	4
270	Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data. Pediatric Infectious Disease Journal, 2014, 33, 57-62.	1.1	4

#	Article	IF	CITATIONS
271	Optimizing Research Methods to Understand HIV-Exposed Uninfected Infant and Child Morbidity: Report of the Second HEU Infant and Child Workshop. Frontiers in Immunology, 2016, 7, 576.	2.2	4
272	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatric Infectious Disease Journal, 2019, 38, 400-405.	1.1	4
273	Hospitalization in South African Adolescents With Perinatally Acquired HIV on Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2020, 39, 1035-1039.	1.1	4
274	Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines. Vaccine, 2020, 38, 2651-2659.	1.7	4
275	Cortical structural changes related to early antiretroviral therapy (ART) interruption in perinatally HIV-infected children at 5 years of age. IBRO Neuroscience Reports, 2021, 10, 161-170.	0.7	4
276	Multivariate approach for longitudinal analysis of brain metabolite levels from ages 5-11 years in children with perinatal HIV infection. NeuroImage, 2021, 237, 118101.	2.1	4
277	Altered White Matter Tracts in the Somatosensory, Salience, Motor, and Default Mode Networks in 7-Year-Old Children Living with Human Immunodeficiency Virus: A Tractographic Analysis. Brain Connectivity, 2022, 12, 302-319.	0.8	4
278	Abacavir: it's use and hypersensitivity. Southern African Journal of HIV Medicine, 2009, 10, 81.	0.3	4
279	Disclosure of human immunodeficiency virus status to children in South Africa: A comprehensive analysis. Southern African Journal of HIV Medicine, 2019, 20, 884.	0.3	4
280	Arginine vasopressin concentrations in the cerebrospinal fluid of children. Child's Nervous System, 1991, 7, 399-401.	0.6	3
281	Monotherapy in an era of combination therapy: is there a benefit? Experience in HIV-1-infected symptomatic South African children. Annals of Tropical Paediatrics, 2000, 20, 185-192.	1.0	3
282	Postnatal Zidovudine in Prevention of Vertical HIV-1 Transmission in a Service Setting. Journal of Tropical Pediatrics, 2001, 47, 215-219.	0.7	3
283	Antiretroviral Therapy in Children with Tuberculosis: Progress toward Defining the Issues. Journal of Infectious Diseases, 2010, 201, 1113-1114.	1.9	3
284	Fatal Hepatitis B Infection Despite Immunization in an HIV-infected Infant: A Possible Case of Vaccine Failure and Immune Reconstitution Inflammatory Syndrome. Journal of Tropical Pediatrics, 2010, 56, 351-354.	0.7	3
285	Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. BMC Pediatrics, 2011, 11, 104.	0.7	3
286	Group B streptococcal disease in infants. Lancet, The, 2012, 379, 502-503.	6.3	3
287	Commentary: minimizing the risk of non-vertical, non-sexual HIV infection in children – beyond mother to child transmission. Journal of the International AIDS Society, 2012, 15, 17377.	1.2	3
288	Biceps Skin-fold Thickness May Detect and Predict Early Lipoatrophy in HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, e254-e262.	1.1	3

#	Article	IF	CITATIONS
289	Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?. Paediatrics and International Child Health, 2014, 34, 138-141.	0.3	3
290	Utilization of paediatric isolation facilities in a TB-endemic setting. Antimicrobial Resistance and Infection Control, 2015, 4, 36.	1.5	3
291	Clinical features and lung function in HIV-infected children with chronic lung disease. SAJCH South African Journal of Child Health, 2015, 9, 72.	0.2	3
292	Late-Onset Hiv Encephalopathy In Children With Long-Standing Virologic Suppression Followed By Slow Spontaneous Recovery Despite no Change In Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2017, 36, e264-e267.	1.1	3
293	Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age. Pediatric Infectious Disease Journal, 2018, 37, e149-e156.	1.1	3
294	Considerations in evaluating infectious morbidity and mortality in HIV-exposed uninfected infants. Aids, 2018, 32, 2855-2856.	1.0	3
295	Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. PLoS ONE, 2018, 13, e0194132.	1.1	3
296	Factors influencing access of pregnant women and their infants to their local healthcare system: a prospective, multi-centre, observational study. BMC Pregnancy and Childbirth, 2018, 18, 29.	0.9	3
297	Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
298	Human Immunodeficiency Virus–exposed Uninfected Infants: Surviving and Thriving or Overlooked by Success?. Clinical Infectious Diseases, 2019, 68, 2156-2158.	2.9	3
299	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. PLoS ONE, 2020, 15, e0238839.	1.1	3
300	Diffusion tensor imaging point to ongoing functional impairment in HIV-infected children at age 5, undetectable using standard neurodevelopmental assessments. AIDS Research and Therapy, 2020, 17, 20.	0.7	3
301	Presumed Cytomegalovirus Retinitis in Human Immunodeficiency Virus Type I-infected South African Children. Pediatric Infectious Disease Journal, 2011, 30, 539-540.	1.1	3
302	Nosocomial Pneumonia in Pediatric Patients. Paediatric Drugs, 2002, 4, 73-83.	1.3	3
303	An analysis of the HIV testing cascade of a group of HIV-exposed infants from birth to 18 months in peri-urban Khayelitsha, South Africa. PLoS ONE, 2022, 17, e0262518.	1.1	3
304	Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clinical Infectious Diseases, 2022, 75, 1037-1045.	2.9	3
305	The effect of oral iron supplementation on the gut microbiota, gut inflammation, and iron status in iron-depleted South African school-age children with virally suppressed HIV and without HIV. European Journal of Nutrition, 2022, 61, 2067-2078.	1.8	3
306	Dental abscesses as a cause of 'unexplained' recurrent fever in a 9-year-old boy. South African Medical Journal, 1999, 89, 841-2.	0.2	3

#	Article	IF	CITATIONS
307	Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Medical Research Methodology, 2022, 22, 49.	1.4	3
308	Population pharmacokinetics of ethambutol in African children: a pooled analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1949-1959.	1.3	3
309	Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients. European Journal of Immunology, 2022, , .	1.6	3
310	Candidal Suppurative Thrombophlebitis in a Premature Infant. JAMA Pediatrics, 1988, 142, 254.	3.6	2
311	Letter. Upper airway obstruction in an HIV-1 infected child with acute Epstein-Barr virus infection. Journal of Tropical Pediatrics, 1999, 45, 119-120.	0.7	2
312	Initiating anti-retroviral therapy in HIV-infected infants and children. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2006, 48, 54-59.	0.2	2
313	Another Milestone in Minimizing Risks to Mothers Exposed to Singleâ€Dose Nevirapine for Prevention of Vertical Transmission of HIVâ€I to Infants: What Next?. Clinical Infectious Diseases, 2010, 50, 909-911.	2.9	2
314	Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041. International Journal of Tuberculosis and Lung Disease, 2017, 21, 38-45.	0.6	2
315	Is point-of-care early infant HIV diagnosis sustainable?. Lancet HIV,the, 2019, 6, e344-e345.	2.1	2
316	Naive B Cell Output in HIV-Infected and HIV-Uninfected Children. AIDS Research and Human Retroviruses, 2019, 35, 33-39.	0.5	2
317	HIV outbreak in children in Pakistan: localised or more widespread?. Lancet Infectious Diseases, The, 2020, 20, 269-270.	4.6	2
318	Profile of Young South African Children Hospitalized With HIV: Cause for Concern. Pediatric Infectious Disease Journal, 2020, 39, 840-842.	1.1	2
319	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 2022, 88, 403-415.	1.1	2
320	Viral hepatitis B and C in HIV-exposed South African infants. BMC Pediatrics, 2020, 20, 563.	0.7	2
321	HIV sero-conversion during late pregnancy – when to retest. Southern African Journal of HIV Medicine, 2013, 14, 90-92.	0.3	2
322	Comparative study of different brands of stavudine capsules for the off-label 'opened capsule' dosing method recommended for HIV-infected infants and children in resource-limited settings. SAJCH South African Journal of Child Health, 2009, 3, 44-47.	0.2	2
323	Childhood lung function following perinatal HIV infection and early antiretroviral therapy initiation; a cross-sectional study. ERJ Open Research, 2022, 8, 00691-2021.	1.1	2
324	OCCUPATIONAL EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS IN PEDIATRICIANS: A PREVIOUSLY UNDESCRIBED HIGH RISK GROUP. Pediatric Infectious Disease Journal, 2003, 22, 382-383.	1.1	1

#	Article	IF	CITATIONS
325	Radiology services for children in HIV- and TB-endemic regions: scope for greater collaboration between radiologists and clinicians caring for children. Pediatric Radiology, 2009, 39, 541-544.	1.1	1
326	Atypical features of congenital syphilis in an HIVâ€exposed uninfected neonate. Pediatrics International, 2010, 52, 332-333.	0.2	1
327	Evaluating antibiotic use in a secondary level hospital neonatal unit in the Western Cape, South Africa. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2010, 25, 21-25.	0.2	1
328	Paediatric Antiretroviral Drug Targets. Infectious Disorders - Drug Targets, 2011, 11, 115-123.	0.4	1
329	Comment on: "Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia― Drug Safety, 2015, 38, 931-931.	1.4	1
330	Healthcare-associated infections in children: knowledge, attitudes and practice of paediatric healthcare providers at Tygerberg Hospital, Cape Town. Paediatrics and International Child Health, 0, , 1-7.	0.3	1
331	Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma. Metabolic Brain Disease, 2018, 33, 537-544.	1.4	1
332	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	1
333	Streptococcus pneumoniae colonization in pneumococcal vaccine-naÃ ⁻ ve human immunodeficiency virus-exposed infected and -uninfected South African children. Medicine (United States), 2020, 99, e19353.	0.4	1
334	Malaria in Children - Prevention and Management. Infectious Disorders - Drug Targets, 2014, 13, 303-311.	0.4	1
335	When to start antiretroviral therapy in infants and children. Southern African Journal of HIV Medicine, 2009, 10, 50.	0.3	1
336	Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens. Open AIDS Journal, 2015, 9, 38-44.	0.1	1
337	Multimodal magnetic resonance neuroimaging measures characteristic of early <scp>cART</scp> â€ŧreated pediatric <scp>HIV</scp> : A feature selection approach. Human Brain Mapping, 2022, 43, 4128-4144.	1.9	1
338	updAIDS in SA Family Practice. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2006, 48, 34-41.	0.2	0
339	The diagnosis and management of tuberculosis in HIV-infected children. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2006, 21, 9-13.	0.2	0
340	Maintaining infants and children on highly active antiretroviral therapy. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2006, 48, 55-60.	0.2	0
341	Cochrane review: Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Evidence-Based Child Health: A Cochrane Review Journal, 2009, 4, 1428-1444.	2.0	0
342	PEDIATRIC AND ADOLESCENT IMPORTED MALARIA IN CAPE TOWN. Pediatric Infectious Disease Journal, 2009, 28, 644-646.	1.1	0

#	Article	IF	CITATIONS
343	Unsuspected fatal drug-resistant TB in a child. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2010, 25, 30-32.	0.2	0
344	Antiretroviral and Antituberculosis Therapy in HIV-TB Co-Infected Children. Current Pediatric Reviews, 2011, 7, 173-179.	0.4	0
345	A case of congenital measles during the 2010 South African epidemic. Annals of Tropical Paediatrics, 2011, 31, 185-188.	1.0	0
346	HIV/AIDS in Children. , 2014, , 97-99.e1.		0
347	Universal children's day – let's improve current interventions to reduce vertical transmission of HIV now. Journal of the International AIDS Society, 2014, 17, 19875.	1.2	0
348	Maintenance of antiretroviral efficacy in children. Lancet HIV,the, 2015, 2, e120-e121.	2.1	0
349	Willingness of tobacco smokers to contribute financially towards cessation resources. South African Medical Journal, 2016, 106, 1154.	0.2	0
350	Hope of post-treatment control after perinatal infection?. Lancet HIV,the, 2016, 3, e6-e8.	2.1	0
351	Re. Pediatric Infectious Disease Journal, 2017, 36, 241-242.	1.1	0
352	Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 151-155.	0.4	0
353	Essential metrics for high-quality reporting of neonatal sepsis research in low-resource settings. Lancet Infectious Diseases, The, 2019, 19, 1155-1157.	4.6	0
354	What Will It Take to Implement Targeted HIV Testing at Birth?. Pediatrics, 2019, 143, e20190913.	1.0	0
355	Should efavirenz be used in children and, if so, how?. Lancet HIV,the, 2019, 6, e210-e211.	2.1	0
356	Abacavir Dosing in Neonates from Birth to 3 Months of Life. SSRN Electronic Journal, 0, , .	0.4	0
357	Follow-up of a BCG trial after 30 years: what lessons have we learned?. The Lancet Global Health, 2021, 9, e1353-e1354.	2.9	0
358	Treating HIV-infected children. Southern African Journal of HIV Medicine, 2009, 10, 5.	0.3	0
359	Managing the HIV-infected neonate: A rural doctor's perspective. Southern African Journal of HIV Medicine, 2014, 15, 119.	0.3	0
360	Tuberculosis and HIV in Children. , 2020, , 181-201.		0

#	Article	IF	CITATIONS
361	Room for Improvement: Results of a Baseline Evaluation of Environmental Cleaning in a Resource-Limited Neonatal Unit. Infection Control and Hospital Epidemiology, 2020, 41, s50-s51.	1.0	0
362	Dental abscesses as a cause of 'unexplained' recurrent fever in a 9-year-old boy. South African Dental Journal, 2000, 55, 166-7.	0.2	0
363	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
364	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
365	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
366	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
367	Approach to the management of paediatric HIV spontaneous controllers. Southern African Journal of Infectious Diseases, 2022, 37, .	0.3	Ο